ArticleMedical physics2026
Multi-fidelity Monte Carlo fusion for BNCT dose calculation using a dual-branch network.
Article in Medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBoron neutron capture therapy (BNCT) is a binary radiotherapy that selectively kills tumor cells. Its clinical implementation relies on Monte Carlo (MC)-based treatment planning systems, which are time-consuming and limit clinical workflow efficiency. PURPOSE: To address this limitation, we propose a Multi-Fidelity MC-based Dual-Branch Network (MFMC-DBN) that leverages complementary information from low- and high-fidelity MC simulations through dual-branch feature fusion, enabling accurate and efficient BNCT dose calculation.
methodsThe model was trained, validated, and tested using clinical data from 112 glioblastoma patients. Low-statistics coarse and fine mesh MC dose distributions (6.5×10
resultsMFMC-DBN outperformed both the NN and MC denoising methods across evaluated metrics. It achieved a mean absolute percentage error (MAPE) of 1.98% in the gross tumor volume (GTV). Organ-specific MAPEs ranged from 1.1% to 3.9%, with a maximum mean absolute error (MAE) of0.28 Gy (RBE). Gamma analysis further showed high spatial agreement, with passing rates of 99.8% within the patient contour and 99.3% in the GTV under the 3%/3 mm criterion. The proposed method maintained high dosimetric accuracy while substantially accelerating BNCT dose calculation.
conclusionsMFMC-DBN effectively integrates multi-fidelity MC information through a dual-branch attention mechanism, enabling rapid and accurate 3D BNCT dose prediction. By significantly reducing computation time compared with full MC simulations while preserving dosimetric fidelity, these results support the feasibility of the proposed framework for accelerated BNCT dose calculation under a fixed beam configuration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.